Q-omics provides the consensus-scored SLC25A6 profile across patient tissues and cancer cell-line models. SLC25A6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC25A6 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, SLC25A6 protein abundance shows 18,062 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, LIHC, and GBM as cancer lineages where SLC25A6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC25A6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC25A6 survival associations across molecular data types. SLC25A6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC25A6 RNA expression–survival associations across cancer types. High SLC25A6 expression shows unfavorable associations in LIHC and LUAD, but favorable associations in UVM, MESO, PAAD and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC25A6 RNA expression.
This table summarizes SLC25A6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC25A6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC25A6 shows lower tumor expression in THCA and BRCA and higher tumor expression in LIHC, COAD, KIRC and CHOL. The LIHC box plot shows higher SLC25A6 RNA expression in tumor versus normal tissue (log2 FC = +1.680, t-test p < 0.001).
This table shows molecular features associated with SLC25A6 in patient tissues and cancer cell lines. In patient samples, SLC25A6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC25A6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SKIN.
